We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
McKesson (MCK - Free Report) ended the recent trading session at $730.80, demonstrating a +1.82% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%.
Shares of the prescription drug distributor witnessed a gain of 5.2% over the previous month, beating the performance of the Medical sector with its gain of 4.64%, and underperforming the S&P 500's gain of 6.6%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is forecasted to report an EPS of $8.35, showcasing a 5.96% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $95.77 billion, up 20.79% from the prior-year quarter.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $37.21 per share and revenue of $405.8 billion. These results would represent year-over-year changes of +12.59% and +13.02%, respectively.
It is also important to note the recent changes to analyst estimates for McKesson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.11% lower. As of now, McKesson holds a Zacks Rank of #3 (Hold).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 19.29. This indicates a premium in contrast to its industry's Forward P/E of 17.96.
We can additionally observe that MCK currently boasts a PEG ratio of 1.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Dental Supplies industry had an average PEG ratio of 1.75.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 67, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Rises Higher Than Market: Key Facts
McKesson (MCK - Free Report) ended the recent trading session at $730.80, demonstrating a +1.82% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%.
Shares of the prescription drug distributor witnessed a gain of 5.2% over the previous month, beating the performance of the Medical sector with its gain of 4.64%, and underperforming the S&P 500's gain of 6.6%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is forecasted to report an EPS of $8.35, showcasing a 5.96% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $95.77 billion, up 20.79% from the prior-year quarter.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $37.21 per share and revenue of $405.8 billion. These results would represent year-over-year changes of +12.59% and +13.02%, respectively.
It is also important to note the recent changes to analyst estimates for McKesson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.11% lower. As of now, McKesson holds a Zacks Rank of #3 (Hold).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 19.29. This indicates a premium in contrast to its industry's Forward P/E of 17.96.
We can additionally observe that MCK currently boasts a PEG ratio of 1.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Dental Supplies industry had an average PEG ratio of 1.75.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 67, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.